SARS-CoV-2 Associated Respiratory Failure in a Preterm Infant and the Outcome after Remdesivir Treatment

Mohammed A Sarhan; Maria Casalino; Pongsatorn Paopongsawan; David Gryn; Tapas Kulkarni; Ari Bitnun; Estelle B Gauda

doi:10.1097/INF.0000000000003504

SARS-CoV-2 Associated Respiratory Failure in a Preterm Infant and the Outcome after Remdesivir Treatment

Pediatr Infect Dis J. 2022 May 1;41(5):e233-e234. doi: 10.1097/INF.0000000000003504.

Authors

Mohammed A Sarhan^{1

2}, Maria Casalino³, Pongsatorn Paopongsawan^{4

5}, David Gryn⁶, Tapas Kulkarni⁴, Ari Bitnun², Estelle B Gauda⁴

Affiliations

¹ From the Division of Medical Microbiology, Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Canada.
² Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Canada.
³ Laboratory Medicine and Pathobiology, Faculty of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
⁴ Division of Neonatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Canada.
⁵ Department of Pediatrics, Faculty of Medicine, University of Khon Kaen, Thailand.
⁶ Department of Pediatrics, Mackenzie Health, Richmond Hill, Ontario.

Abstract

Severe coronavirus disease 2019 (COVID-19) occurs in approximately 10% of neonates infected with severe acute respiratory syndrome coronavirus 2. Guidelines for optimal management of severe COVID-19 in neonates do not exist. In this report, we describe a late-preterm neonate with severe COVID-19, requiring invasive mechanical ventilation who recovered following treatment with remdesivir and high dose dexamethasone.

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
COVID-19 Drug Treatment*
Humans
Infant
Infant, Newborn
Infant, Premature
Respiratory Insufficiency*
SARS-CoV-2

Substances

remdesivir
Adenosine Monophosphate
Alanine